SEC EDGARSEP 31 min read$MIRM

Howe Jolanda sold $66K of MIRM

Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 658 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $100.00 on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Howe Jolanda

Published Sep 3, 2026, 10:54 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 3, 2026, 11:33 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MIRM

Bearish

high confidence

Mentioned

$MIRM

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MIRMBearishLow

Why it matters

The disclosed sale is modest and unlikely to affect market perception significantly.

Market read

Routine insider sale with minimal trading relevance.

What to watch

Potential upcoming clinical data releases that could amplify the effect of any insider trading.

Relevance 2/10Novelty 2/10Timing: post‑market 2026‑09‑02 filing

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MIRMBearishHigh confidence

Context

SVP Howe Jolanda sold 658 shares of Mirum Pharmaceuticals for $65,800 via a 10b5-1 plan, reducing his holding to 616 shares.

Expected impact

Minor dip or flat price action; no material impact.

Evidence & confidence

The transaction size ($66K) is trivial relative to market cap; insider sales of this magnitude rarely move the price.

Market effects

Sector

No broader sector impact; mirrors routine insider activity in biotech.

Regional

Limited to U.S. investors tracking Mirum.

Global

None

Counterpoint

What could challenge this read

If the insider is reducing exposure ahead of negative news, the stock could face a sharper sell‑off.

Key entities

Company
Mirum Pharmaceuticals, Inc.
Biopharmaceutical company developing treatments for metabolic diseases.
Insider
Howe Jolanda
Senior Vice President, Global Controller at Mirum.

Read at source ← All news

OCT 4

$INCYHighAI 9/10

Incyte Wins FDA Approval for Rare Bone Disease Drug

Incyte (INCY) received FDA approval for Atebrioz, a treatment for fibrodysplasia ossificans progressiva. The drug, licensed to Mirum Pharmaceuticals (MIRM), showed a 3.2 cm³ reduction in lesion volume in trials. Incyte also received a Rare Pediatric Disease Priority Review Voucher. Mirum plans U.S. launch in October.

mychesco.com2 min

OCT 3

$MIRMMedAI 9/10

[Press release] Mirum Pharmaceuticals announces primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus

Mirum Pharmaceuticals reported that its Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus met its primary endpoint. The 48-week Phase 2b data showed deepening viral suppression and increased ALT normalization. AZURE-1 is part of the U.S. registration package for brelovitug.

eatg.org1 min

OCT 2

$MIRMMedAI 8/10

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

Mirum Pharmaceuticals (MIRM) announced positive Phase III results for brelovitug in hepatitis delta treatment, with 25% of patients achieving viral suppression. The company plans to submit a biologics license application in early 2025 and expects peak sales of at least $1 billion. Additionally, Mirum received FDA approval for Atebrioz, its fourth commercial medicine, targeting heterotopic ossification in FOP patients.

finance.yahoo.com2 min

OCT 2

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min

SEP 30

$MIRMMedAI 8/10

Mirum Plans 2027 Hepatitis D Filing After Phase 3 Win as U.S. Patients Rely on One Approved Drug

Mirum Pharmaceuticals' brelovitug met primary goals in a Phase 3 trial for hepatitis D. The company plans FDA approval filing in early 2027. Currently, only one drug, Gilead's Hepcludex, is approved in the U.S. for certain patients.

medicaldaily.com3 min

SEP 28

$MIRMHighAI 9/10

FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

Mirum Pharmaceuticals received FDA approval for Atebrioz (zilurgisertib) to treat fibrodysplasia ossificans progressiva (FOP), a rare bone disease. The drug, a once-daily pill, showed significant reduction in new lesion volume in clinical trials. Mirum joins Regeneron and Ipsen in offering treatments for FOP, with Atebrioz being the third approved option in recent months. The company plans to launch the drug in October, with pricing details to be announced.

biospace.com2 min